… About ProQR Therapeutics An innovative biotech company advancing … Axiomer RNA-editing platform technology. We are ProQR We are ProQR We are ProQR, a biotechnology company dedicated to …
… ProQR founding story When our CEO, Daniel A. de Boer, knew … his newborn son had an incurable rare disease, he founded ProQR to help people like his son. Learn more. A personal … a difference in the world. Daniel continues to motivate ProQRians to remind them of the company’s mission and to …
LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V. (Euronext & NASDAQ:GLPG).
… ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets Agreement … FERRAND, France, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company …
… European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10 Access … vision with sepofarsen,” stated Daniel A. de Boer, CEO of ProQR. “Looking ahead, our goal is for sepofarsen to reach …
